文献速递神经介入DSA

血管紧张素转换酶抑制剂对颅内动脉瘤血管内治疗结局的影响

Impact of angiotensin-converting-enzyme inhibitors on intracranial aneurysm endovascular treatment outcome.
PubMed 文献 · Neuroradiology · 2026-03-17

单中心回顾性观察队列研究纳入2015年1月至2024年6月住院的未破裂颅内动脉瘤患者,分别接受弹簧圈栓塞或血流导向装置置入,分析ACEI摄入与随访时动脉瘤完全闭塞的关系。结果显示弹簧圈组再通动脉瘤患者ACEI使用比例更高(61.54% vs 31.43%,p<0.01),多因素分析ACEI摄入为首次随访再通的独立预测因子(OR 3.65,95%CI 1.2–11.83,p=0.02);血流导向装置组不完全闭塞患者ACEI使用比例亦更高(36.76% vs 18.51%,p=0.01),ACEI摄入增加首次随访不完全闭塞风险(OR 2.86,95%CI 1.34–6.29,p<0.01)。作者结论认为ACEI摄入可能降低血管内治疗后动脉瘤完全闭塞率。

要点

  • 弹簧圈组首次随访再通动脉瘤患者ACEI使用比例显著更高(61.54% vs 31.43%,p<0.01)。
  • 血流导向装置组首次随访不完全闭塞患者ACEI使用比例更高(36.76% vs 18.51%,p=0.01)。
  • 多因素分析中ACEI摄入为弹簧圈组再通(OR 3.65)和FD组不完全闭塞(OR 2.86)的独立预测因子。

核心结论

  • ACEI摄入可能降低颅内动脉瘤血管内治疗后的完全闭塞率。

研究设计与样本

  • 单中心回顾性观察队列研究,纳入2015年1月至2024年6月住院的未破裂颅内动脉瘤患者;弹簧圈组126例患者131个动脉瘤,血流导向装置组134例患者149个动脉瘤;随访影像于6个月和18个月收集;采用χ2检验和t检验进行单因素分析,多因素分析采用逻辑回归。

诊断标准与关键数值

  • 弹簧圈组首次随访再通动脉瘤患者ACEI使用比例61.54% vs 未再通者31.43%(p<0.01)。
  • 多因素分析中ACEI摄入预测弹簧圈组首次随访再通(OR 3.65,95%CI 1.2–11.83,p=0.02)。
  • 血流导向装置组首次随访不完全闭塞患者ACEI使用比例36.76% vs 完全闭塞者18.51%(p=0.01)。
  • 多因素分析中ACEI摄入增加血流导向装置组首次随访不完全闭塞风险(OR 2.86,95%CI 1.34–6.29,p<0.01)。

临床应用与阅片要点

  • 弹簧圈组基线ACEI使用49例,血流导向装置组40例;接受血流导向或支架辅助弹簧圈治疗者均接受标准抗血小板治疗,无人口服抗凝药。
  • 最常用的ACEI为雷米普利(57.30%)、培哚普利(32.58%)和赖诺普利(10.11%)。
  • 弹簧圈组26个动脉瘤(19.9%)在首次随访影像上再通;血流导向装置组68个动脉瘤(45.64%)在首次随访影像上不完全闭塞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Angiotensin-converting enzyme inhibitors (ACEis) are commonly prescribed antihypertensive medications. They also possess antiplatelet properties. The aim of this single-center retrospective observational cohort study was to analyze whether intake of ACEis may increase the risk of incomplete aneurysm occlusion after this treatment modality. METHODS: We retrospectively included patients hospitalized between January 2015 and June 2024 with unruptured intracranial aneurysm, who underwent endovascular treatment with coiling or Flow Diverter (FD) placement. Imaging data (at 6 months and 18 months follow-up) were collected. We gathered information about the occlusion status at both follow-up examinations. Univariate analysis was conducted using χ2 and t-tests, and multivariate analysis employed logistic regression. RESULTS: A total of 126 patients with 131 aneurysms were included in coiling group and 134 patients with 149 aneurysms were included in FD group. At baseline, ACEis were used by 49 patients in the coiling group and 40 patients in the flow diverter group. Patients treated with flow diversion or stent-assisted coiling received standard antiplatelet therapy and none were on oral anticoagulation. The most commonly used ACEis were ramipril (57.30%), perindopril (32.58%), and lisinopril (10.11%). Twenty-six aneurysms (19.9%) from the coiling group were recanalized on the first follow-up examination. Patients with recanalized aneurysms were significantly more likely to take ACEis (61.54% vs. 31.43%; p < 0.01). In multivariable analysis, the logistic regression model identified aneurysm ACEis intake (OR:3.65;95% CI:1.2–11.83;p = 0.02) as an independent predictor of aneurysm recanalization at the first follow-up. Sixty-eight aneurysms (45.64%) from the FD group were incompletely occluded at the first follow-up examination. Similarly to coiling group, patients with non-totally occluded aneurysms were more likely to take ACEis (36.76% vs. 18.51%;p = 0.01). In multivariate analysis, intake of ACEis (OR:2.86;95% CI:1.34–6.29;p < 0.01) significantly increased risk of incomplete occlusion at first follow-up. CONCLUSIONS: ACEis intake might reduce the rate of total aneurysm occlusion after endovascular treatment.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Kliś KM, Brzegowy P, Cierniak A, et al. Impact of angiotensin-converting-enzyme inhibitors on intracranial aneurysm endovascular treatment outcome. Neuroradiology. 2026. PMID: 41843104. doi:10.1007/s00234-026-03972-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。